Medical Imaging and Radiography Department, Aqaba University of Technology, Aqaba, Jordan.
Department of Physical Therapy, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Jordan.
J Infect Dev Ctries. 2024 May 30;18(5):666-671. doi: 10.3855/jidc.18593.
Coronavirus 2019 symptoms include coagulopathy and thromboembolic risk. Using one parameter to diagnose coagulopathy has little predictive value.
This study will examine if D-dimer and APTT testing can predict COVID-19 severity and aid triage and manage patients.
214 COVID-19 patients were enrolled and classified into two categories based on their respiratory manifestations; mild (126 cases) and severe (88 cases). Patient data regarding age, gender, D-Dimer level, and APTT level were collected. When both D-Dimer and APTT levels were abnormal, in this study, the patient was considered to have a coagulation disorder. Indicators of coagulation in the COVID-19 patients were collected and compared between the two groups. Chi-square (χ2) tests were used to determine the significant differences between coagulation disorders in the two groups.
Our findings showed that patients with coagulopathies were more likely to belong to the severe group. Within the two groups of patients, the rate of coagulation disorders was as follows: mild = 8.8 % within coagulation disorders, 4.8% within the two Groups; severe = 91.2 % within coagulation disorders, 77.8 % within the two Groups. There was a statistically significant relationship between coagulation disorder and severe COVID-19 patients compared to mild patients (p < 0.05).
Coagulation disorders are more likely to occur in severe COVID-19 patients. D-Dimer and APTT tests are significant indicators for predicting COVID-19 severity. Our research found an abnormal pattern of coagulation disorders and COVID-19 severity that should be considered in the COVID-19 treatment protocol.
2019 年冠状病毒病的症状包括凝血功能障碍和血栓栓塞风险。使用单一参数来诊断凝血功能障碍的预测价值不大。
本研究旨在探讨 D-二聚体和 APTT 检测是否可以预测 COVID-19 的严重程度，并辅助分诊和管理患者。
共纳入 214 例 COVID-19 患者，根据其呼吸道表现分为两组：轻症（126 例）和重症（88 例）。收集患者的年龄、性别、D-二聚体水平和 APTT 水平等数据。在本研究中，当 D-二聚体和 APTT 水平均异常时，认为患者存在凝血障碍。收集 COVID-19 患者的凝血指标，并比较两组之间的差异。采用卡方检验（χ2 检验）比较两组患者凝血障碍的差异。
我们的研究结果表明，凝血障碍患者更可能属于重症组。在两组患者中，凝血障碍的发生率分别为：轻症组中凝血障碍的发生率为 8.8%，两组患者中凝血障碍的发生率为 4.8%；重症组中凝血障碍的发生率为 91.2%，两组患者中凝血障碍的发生率为 77.8%。与轻症患者相比，重症 COVID-19 患者中凝血障碍具有统计学显著差异（p<0.05）。
凝血障碍更可能发生在重症 COVID-19 患者中。D-二聚体和 APTT 检测是预测 COVID-19 严重程度的重要指标。我们的研究发现了 COVID-19 严重程度与凝血障碍异常模式之间的关系，这在 COVID-19 治疗方案中应予以考虑。
